Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

lipid-specific IgM bands in csf associated with a reduced risk of developing pml during treatment with natalizumab.
The unidimensional self-efficacy scale for MS (USE-MS): developing a patient based and patient reported outcome.
Accelerated lymphocyte recovery after alemtuzumab does not predict multiple sclerosis activity.
Efficacy and safety of interferon beta-1b sc in older RRMS patients--a posthoc analysis of the BEYOND study.
Conformational Landscape of N-Glycosylated Peptides Detecting Autoantibodies in Multiple Sclerosis, Revealed by Hamiltonian Replica Exchange.
Laminin-411 Is a Vascular Ligand for MCAM and Facilitates TH17 Cell Entry into the CNS.
Molecular properties of epithelial, amiloride-blockable Na+ channels.
Activities of daily living: evaluation and treatment in persons with multiple sclerosis.
Self-perceived performance and satisfaction with performance of daily activities in persons with multiple sclerosis following interdisciplinary rehabilitation.
Daclizumab high-yield process reduced the evolution of new gadolinium-enhancing lesions to T1 black holes in patients with relapsing-remitting multiple sclerosis.
The clinically-tested S1P receptor agonists, FTY720 and BAF312, demonstrate subtype-specific bradycardia (S1P₁) and hypertension (S1P₃) in rat.
[A comparison analysis of the use of intravenous β-interferon-1a 30 mcg and subcutaneous β-interferon-1a 44 mcg in routine clinical practice of treatment in patients with multiple sclerosis].
Multiple sclerosis.
Combined central and peripheral demyelination: Clinical features, diagnostic findings, and treatment.
Exploring the CLEC16A gene reveals a MS-associated variant with correlation to the relative expression of CLEC16A isoforms in thymus.
Materials for stem cell factories of the future.
Amiloride Clinical Trial In Optic Neuritis (ACTION) protocol: a randomised, double blind, placebo controlled trial.
Evaluating more naturalistic outcome measures: A 1-year smartphone study in multiple sclerosis.
Tumefactive multiple sclerosis lesions under fingolimod treatment.
Transverse myelitis -- a review of the presentation, diagnosis, and initial management.
Validation of a Dutch version of the Neurological Fatigue Index (NFI-MS) for patients with multiple sclerosis in the Netherlands.
Health Canada Approves PLEGRIDY™ (peginterferon beta-1a) for Adults with Relapsing Remitting Multiple Sclerosis
Inhibition of glycerophosphate-dependent H2O2 generation in brown fat mitochondria by idebenone.
Multiple sclerosis: current and emerging disease-modifying therapies and treatment strategies.
Periventricular lesions help differentiate neuromyelitis optica spectrum disorders from multiple sclerosis.

Pages